Robert Arthur Harrington insider trades: Cytokinetics (CYTK) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Robert reports to the SEC
Open-market buys and sales
6 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Dec 1, 2025 | CYTK | ↓ Sell | 2,150 | $66.80 | $144K | Direct | Dec 2, 2025 (1d) |
| Sep 2, 2025 | CYTK | ↓ Sell | 2,150 | $48.67 | $105K | Direct | Sep 2, 2025 (0d) |
| Apr 3, 2025 | CYTK | ↓ Sell | 450 | $39.43 | $18K | Direct | Apr 4, 2025 (1d) |
| Mar 4, 2025 | CYTK | ↓ Sell | 900 | $42.50 | $38K | Direct | Mar 4, 2025 (0d) |
| Jul 5, 2024 | CYTK | ↓ Sell | 253 | $54.61 | $14K | Direct | Jul 8, 2024 (3d) |
| Jun 3, 2024 | CYTK | ↓ Sell | 1,580 | $48.64 | $77K | Direct | Jun 5, 2024 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other CYTK insiders
Open-market trades in the last 12 months
About Robert Arthur Harrington's insider trades
Robert Arthur Harrington is a director at Cytokinetics (CYTK). Since Jun 3, 2024, Robert has reported no open-market purchases and 6 sales worth $395K on SEC Form 4. In the last 12 months: 1 sale ($144K).
Their filings also include grants and awards (21 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every CYTK insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.